Table 5

Outcome of all 16 patients with del 17p− at registration (intent-to-treat)

UPNAge/sexFISH karyotypePA refractoryDonorStatus at SCTSCT (regimen)Outcome
005004 63/M del 17p− Yes SIB SD Yes (FC) REL +3, died of PD +19 
005008 56/M del 17p− Yes NA (UD) SD Yes (FBC) Alive in CR, 46+ mo (MRD− 46+) 
011002 39/M del 17p−; del 13q− No PMUD NA Yes (FC) REL +3, died of PD +10 
012005 58/M del 17p−; del 13q−; del 11q− Yes MMUD PR2 Yes (FBC) Alive in CR, 43+ mo (MRD− 43+) 
012007 58/F del 17p−; +12; t(14;?) Yes PMUD PR3 Yes (FC) Alive in CR, 38+ mo (MRD− 38+) 
012008 56/M del 17p− No WMUD PR5 Yes (FC) Alive in CR, 39+ mo (MRD− 39+)* 
013001 54/F del 17p− Untested PMUD PR1 Yes (FC) Alive in CR, 59+ mo (MRD− 54+) 
019002 38/F del 17p− Untested NA (UD) PR3 Yes (TCD) REL +21, died of PD +22 
026001 49/M del 17p− Yes NA NA No Died of PD (Richter transformation) +6 mo after registration without being transplanted 
033003 48/F del 17p−; del 13q− Yes PMUD PR3 Yes (TCD) Died of TRM +10 
041008 62/M del 17p− Yes NA NA No Died of PD (Richter transformation) +9 mo after registration without being transplanted 
125012 62/F del 17p− Yes SIB SD Yes REL +3; alive 37+ mo 
125014 58/M del 17p−; del 13q− No WMUD PR5 Yes (FBC) Alive in CR, 18+ mo 
144005 51/F del 17p−; del 11q− Yes PMUD SD Yes (FBC) Alive in CR, 75+ mo (MRD− 59+) 
144011 44/F del 17p− Yes Not found NA No Died of PD +17 mo after registration (no donor) 
144010 43/M del 17p−; del 6q− Untested SIB PR2 Yes (FC) REL +11, died of PD +24 mo 
UPNAge/sexFISH karyotypePA refractoryDonorStatus at SCTSCT (regimen)Outcome
005004 63/M del 17p− Yes SIB SD Yes (FC) REL +3, died of PD +19 
005008 56/M del 17p− Yes NA (UD) SD Yes (FBC) Alive in CR, 46+ mo (MRD− 46+) 
011002 39/M del 17p−; del 13q− No PMUD NA Yes (FC) REL +3, died of PD +10 
012005 58/M del 17p−; del 13q−; del 11q− Yes MMUD PR2 Yes (FBC) Alive in CR, 43+ mo (MRD− 43+) 
012007 58/F del 17p−; +12; t(14;?) Yes PMUD PR3 Yes (FC) Alive in CR, 38+ mo (MRD− 38+) 
012008 56/M del 17p− No WMUD PR5 Yes (FC) Alive in CR, 39+ mo (MRD− 39+)* 
013001 54/F del 17p− Untested PMUD PR1 Yes (FC) Alive in CR, 59+ mo (MRD− 54+) 
019002 38/F del 17p− Untested NA (UD) PR3 Yes (TCD) REL +21, died of PD +22 
026001 49/M del 17p− Yes NA NA No Died of PD (Richter transformation) +6 mo after registration without being transplanted 
033003 48/F del 17p−; del 13q− Yes PMUD PR3 Yes (TCD) Died of TRM +10 
041008 62/M del 17p− Yes NA NA No Died of PD (Richter transformation) +9 mo after registration without being transplanted 
125012 62/F del 17p− Yes SIB SD Yes REL +3; alive 37+ mo 
125014 58/M del 17p−; del 13q− No WMUD PR5 Yes (FBC) Alive in CR, 18+ mo 
144005 51/F del 17p−; del 11q− Yes PMUD SD Yes (FBC) Alive in CR, 75+ mo (MRD− 59+) 
144011 44/F del 17p− Yes Not found NA No Died of PD +17 mo after registration (no donor) 
144010 43/M del 17p−; del 6q− Untested SIB PR2 Yes (FC) REL +11, died of PD +24 mo 

CR indicates complete remission; F, female; FBC, FC + busulfan; FC, fludarabine-cyclophosphamide; FISH, fluorescence in situ hybridization; M, male; MMUD, mismatched unrelated donor; −, negative minimal residual disease; NA, not available; PA, purine analogue; PD, progressive disease; PMUD, partially matched unrelated donor; PR, partial remission; REL, relapse; SCT, stem cell transplantation; SIB, 10/ of 10 allele-matched sibling; TCD, FC + total body irradiation 2Gy + in vivo alemtuzumab; andWMUD, well-matched unrelated donor.

*

This patient was diagnosed with a diffuse large cell lymphoma (DLCL) 9 months after transplant, which was counted as event in the event-free survival analysis. Although a formal proof of clonal identity with the CLL by sequencing was not performed, the fact that paraffin slides of the DLCL were MRD negative with the CLL-specific primers and that the patient became a durably MRD-negative complete donor chimera at the time of DLCL occurrence suggest that DLCL and CLL were not clonally related.